Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-02-2007 | Article

Prevalence of antibiotic resistance in Escherichia coli: overview of geographical, temporal, and methodological variations

Authors: A. Erb, T. Stürmer, R. Marre, H. Brenner

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2007

Abstract

The increase in bacterial antibiotic resistance is of major concern worldwide, but pertinent epidemiologic studies have used strongly divergent approaches and are widely scattered in the literature. The aim of this study was to conduct a systematic review of studies reporting on the prevalence of antibiotic resistance in Escherichia coli in different parts of the world. Studies published from 1970 to 2006 on the prevalence of E. coli resistance were identified by a systematic Medline research and reviewed with respect to characteristics of the study design and study population, the method of resistance detection, and the prevalence of resistance. The prevalence of resistance to specific antibiotics was highly variable in different populations and in different countries and ranged from 0 to 100%. The prevalence of resistance reported in studies from Middle and South America, Spain, and Turkey was higher than that reported in the USA and Central Europe. Moreover, a tendency towards higher prevalence rates of resistance in recent years was observed. The findings indicate a need for regular monitoring of antimicrobial susceptibility rates in different human and animal populations by standardized sampling and measurement procedures. Such monitoring would help identify relevant factors that contribute to the spread of resistant pathogens and would support the prudent use of antibiotics.

Dunne EF, Fey PD, Kludt P, Reporter R, Mostashari F, Shillam P, Wicklund J, Miller C, Holland B, Stamey K, Barrett TJ, Rasheed LK et al (2000) Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC β-lactamase. JAMA 284:3151–3156PubMedCrossRef

Kollef MH, Fraser VJ (2001) Antibiotic resistance in the intensive care unit. Ann Intern Med 134:298–314PubMed

Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, Heine H, Monnickendam MA, Barker KF, James D, George RC (2000) Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. Br Med J 320:213–216CrossRef

Tenover FC, Hughes JM (1996) The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens. JAMA 275:300–304PubMedCrossRef

deMan P, Verhoeven BAN, Verburgh HA, Vos MC, van den Anker JN (2000) An antibiotic policy to prevent emergence of resistant bacilli. Lancet 355:973–978CrossRef

Singer RS, Finch R, Wegener HC, Bywater R, Walters J, Lipsitch M (2003) Antibiotic resistance—the interplay between antibiotic use in animals and human beings. Lancet Infect Dis 3:47–51PubMedCrossRef

Bartoloni A, Bartalesi F, Mantella A, Dell’Amico E, Roselli M, Strohmeyer M, Barahona HG, Barron VP, Paradisi F, Rossolini GM (2004) High prevalence of acquired antimicrobial resistance unrelated to heavy antimicrobial consumption. J Infect Dis 189:1291–1294PubMedCrossRef

Lester SC, del Pilar Pla M, Wang F, Perez Schael I, Jiang H, O’Brien TF (1990) The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. N Engl J Med 323:285–289PubMedCrossRef

Kahlmeter G, ECO.SENS (2003) An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother 51:69–76PubMedCrossRef

10.

Biedenbach DJ, Moet GJ, Jones RN (2004) Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002). Diagn Microbiol Infect Dis 50:59–69PubMedCrossRef

11.

von Baum H, Marre R (2005) Antimicrobial resistance of Escherichia coli and therapeutic implications. Int J Med Microbiol 295:503–511CrossRef

12.

Bonten M, Stobberingh E, Philips J, Houben A (1992) Antibiotic resistance of Escherichia coli in fecal samples of healthy people in two different areas in an industrialized country. Infection 20:258–262PubMedCrossRef

13.

Calva JJ, Sifuentes-Osornio J, Ceron C (1996) Antimicrobial resistance in fecal flora: longitudinal community-based surveillance of children from urban Mexico. Antimicrob Agents Chemother 40:1699–1702PubMed

14.

Dominguez E, Zarazaga M, Saenz Y, Brinas L, Torres C (2002) Mechanisms of antibiotic resistance in Escherichia coli isolates obtained from healthy children in Spain. Microb Drug Resist 8:321–327PubMedCrossRef

15.

Garau J, Xercavins M, Rodriguez-Carballeira M, Gomez-Vera JR, Coll I, Vidal D, Llovet T, Ruiz-Bremon A (1999) Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 43:2736–2741PubMed

16.

Gulay Z, Bicmen M, Amyes SG, Yulug N (2002) Beta-lactamase patterns and betalactam/clavulanic acid resistance in Escherichia coli isolated from fecal samples from healthy volunteers. J Chemother 12:208–215

17.

London N, Nijsten R, van der Bogaard A, Stobberingh E (1994) Carriage of antibiotic-resistant Escherichia coli by healthy volunteers during a 15-week period. Infection 22:187–192PubMedCrossRef

18.

Stürmer T, Erb A, Marre R, Brenner H (2004) Prevalence and determinants of colonisation with antibiotic-resistant Escherichia coli in unselected patients attending general practitioners in Germany. Pharmacoepidemiol Drug Saf 13:303–308PubMedCrossRef

19.

Barrett SP, Savage MA, Rebec MP, Guyot A, Andrews N, Shrimpton SB (2000) Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain. J Antimicrob Chemother 44:359–365CrossRef

20.

Brumfitt W, Faiers MC, Reeves DS, Datta N (1971) Antibiotic-resistant Escherichia coli causing urinary-tract infection in general practice: relation to faecal flora. Lancet 1:315–317CrossRef

21.

Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, Pfaller MA, Doern GV (2000) Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998). J Antimicrob Chemother 45:295–303PubMedCrossRef

22.

Gupta K, Sahm DF, Mayfield D, Stamm WE (2001) Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 33:89–94PubMedCrossRef

23.

Huovinen P, Toivanen P (1980) Trimethoprim resistance in Finland after five years’ use of plain trimethoprim. Br Med J 280:72–74PubMedCrossRef

24.

Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF (2002) Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 46:2540–2545PubMedCrossRef

25.

Vorland LH, Carlson K, Aalen O (1985) Antibiotic resistance and small R plasmids among Escherichia coli isolates from outpatient urinary tract infections in northern Norway. Antimicrob Agents Chemother 27:107–113PubMed

26.

Zhanel GG, Karlowsky JA, Harding GK, Carrie A, Mazzulli T, Low DE, Hoban DJ (2000) A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group. Antimicrob Agents Chemother 44:1089–1092PubMedCrossRef

27.

Zhanel GG, Hisanaga TL, Laing NM, Decorby MR, Nichol KA, Weshnoweski B, Johnson J, Noreddin A, Low DE, Karlowsky JA, for the NAUTICA Group, Hoban DJ (2006) Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA). Int J Antimicrob Agents 27:468–475PubMedCrossRef

28.

Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J (2000) Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 30:454–460PubMedCrossRef

29.

Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J, Spanish members of EARSS (2005) Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg Infect Dis 11:546–553PubMed

30.

Reynolds R, Potz N, Colman M, Williams A, Livermore D, MacGowan A, and the BSAC extended working party on bacteraemia resistance surveillance (2004) Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 53:1018–1032PubMedCrossRef

31.

Shannon KP, French GL (2002) Antibiotic resistance: effect of different criteria for classifying isolates as duplicates on apparent resistance frequencies. J Antimicrob Chemother 49:201–204PubMedCrossRef

32.

Kresken M, Hafner D (1999) Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975–1995. Study group bacterial resistance of the Paul–Ehrlich-society for chemotherapy. Infection 27 (Suppl 2):2–8

33.

Gould IM (2000) Towards a common susceptibility testing method. J Antimicrob Chemother 45:757–762PubMedCrossRef

34.

Chulain MN, Murray AM, Corbett-Feeney G, Cormican M (2005) Antimicrobial resistance in E. coli associated with urinary tract infection in the west of Ireland. Ir J Med Sci 174:6–9PubMedCrossRef

35.

Bartolini A, Pallecchi L, Benedetti M, Fernandez C, Vallejos Y, Guzman E, Villagran AL, Mantella A, Lucchetti C, Bartalesi F, Strohmeyer M, Bechini A, et al (2006) Multidrug-resistant commensal Escherichia coli in children, Peru and Bolivia. Emerg Infect Dis 12:907–913

36.

Ishii Y, Alba J, Kimura S, Yamaguchi K (2006) Evaluation of antimicrobial activity of beta-lactam antibiotics by E test against clinical isolates from 100 medical centers in Japan (2004). Diagn Microbiol Infect Dis 55:143–148PubMedCrossRef

37.

Paterson DL, Bonomo RA (2005) Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 18:657–686PubMedCrossRef

38.

Pitout JD, Hanson ND, Church DL, Laupland KB (2004) Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis 38:1736–1741PubMedCrossRef

39.

Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, Perez-Cano R, Pascual A (2004) Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42:1089–1094PubMedCrossRef

40.

Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, Raz R (2004) Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 23:163–167PubMedCrossRef

41.

Davison HC, Low JC, Woolhouse MEJ (2000) What is antibiotic resistance and how can we measure it? Trends Microbiol 8:554–559PubMedCrossRef

Title: Prevalence of antibiotic resistance in Escherichia coli: overview of geographical, temporal, and methodological variations
Authors: A. Erb
T. Stürmer
R. Marre
H. Brenner
Publication date: 01-02-2007
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2007
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-006-0248-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2007

Safety and tolerability of clarithromycin administered to children at higher-than-recommended doses

Evaluation of the GenoType MTBC assay for differentiating 120 clinical Mycobacterium tuberculosis complex isolates

Human bocavirus DNA detected by quantitative real-time PCR in two children hospitalized for lower respiratory tract infection

Penetration of levofloxacin into the anterior chamber (aqueous humour) of the human eye after intravenous administration

Evaluation of three rapid assays for detection of Clostridium difficile toxin A and toxin B in stool specimens

Rapid detection of Panton–Valentine leukocidin-positive Staphylococcus aureus by real-time PCR targeting the lukS-PV gene

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials